J Rheum Dis.  2017 Oct;24(5):251-252. 10.4078/jrd.2017.24.5.251.

Association between Treatment with Biologic Agents and the Incidence of Herpes Zoster in Rheumatoid Arthritis

• Lim DH
• Kim YG

• KMID: 2394339
• DOI: http://doi.org/10.4078/jrd.2017.24.5.251

Abstract

No abstract available.

MeSH Terms

Arthritis, Rheumatoid*
Biological Factors*
Herpes Zoster*
Incidence*
Biological Factors

Reference

1. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002; 347:340–6.

2. Cheong C, Lee TJ. Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses. Epidemiol Health. 2014; 36:e2014012.

3. Lim DH, Kim YJ, Kim SO, Hong S, Lee CK, Yoo B, et al. The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service – Sample cohort database. Mod Rheumatol. 2017; 1–6.

4. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007; 57:1431–8.

5. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009; 301:737–44.

6. García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010; 69:1751–5.

7. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009; 48:1364–71.

8. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of antitumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013; 309:887–95.

9. Kwon HM, Lee SJ, Yang JA, Choi YH, Park JK, Lee EY, et al. Risk of herpes zoster in patients with rheumatoid arthritis undergoing biologic disease-modifying therapy. J Rheum Dis. 2017; 24:220–6.

10. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013; 72:229–34.

11. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015; 67:731–6.

12. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64:625–39.

13. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66:2675–84.